• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to project page

2023 Fiscal Year Final Research Report

Biomaterials for preemptive treatments of fibrosis

Research Project

  • PDF
Project/Area Number 22K19925
Research Category

Grant-in-Aid for Challenging Research (Exploratory)

Allocation TypeMulti-year Fund
Review Section Medium-sized Section 90:Biomedical engineering and related fields
Research InstitutionKonan University

Principal Investigator

NAGAHAMA KOJI  甲南大学, フロンティアサイエンス学部, 教授 (00551847)

Project Period (FY) 2022-06-30 – 2024-03-31
Keywords線維症 / 先制治療 / TGF-β1 / 線維芽細胞 / ハイドロゲル / PLGA-PEG-PLGA / LAPONITE
Outline of Final Research Achievements

When a hydrogel composed of anionic nanoparticles LAPONITE and biodegradable polymer PLGA-PEG-PLGA is administered to an inflamed site, LAPONITE adsorbs cationic TGF-β1, concentrating it in the gel, and preventing it to transmit surrounding tissues. In addition to preventing diffusion, the PLGA-PEG-PLGA gel network acted as a physical barrier to prevent fibroblasts from entering the gel, suppressing fibroblast activation and preventing the onset of fibrosis. This gel is degradable and disappears after preventing fibrosis, so it does not interfere with tissue reconstruction, and the composite gel induces tissue regeneration. To date, there is no technology to induce skin regeneration without cell transplantation, and the composite gel is useful in developing skin regeneration technology.

Free Research Field

バイオマテリアル

Academic Significance and Societal Importance of the Research Achievements

従来の線維症研究では、線維化が起こった後にTGF-β1と線維芽細胞を薬剤で阻害する戦略が用いられている。これに対して、本研究で提案する『局所作用型バイオマテリアルを用いて、TGF-β1と線維芽細胞の時空間的配置を制御するマイルドな方法で、TGF-β1による線維芽細胞の活性化を慢性炎症部位局所的に防ぎ、副作用なしで線維化を未然に防ぐコンセプト』は世界初である。線維症発症の機構はすべての組織で共通しているため、複合ゲルは心臓、肝臓、腎臓などにも適用できると期待される。将来的に線維症先制治療技術を開発できれば、線維症関連分野の基礎および応用研究にパラダイムシフトをもたらす。

URL: 

Published: 2025-01-30  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi